EP0088540A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
DNA sequences, recombinant DNA molecules and processes for producing human immune interferon-like polypeptides
Assignee: Biogen Inc
•
Filing: 1983-02-17
•
Granted: —
•
Expires: 2003-02-17
Abstract
Abstract DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human immune interferon, the genes coding for these polypeptides and methods of making and using these DNA sequences, molecules, hosts, genes and polypeptides. The DNA sequences are characterized in that they code for a polypeptide displaying a biological or immunological activity of human immune interferon. They also produce such polypeptides having appropriate glycosylation. In appropriate hosts these DNA sequences and recombinant DNA molecules permit the production and identification of genes and polypeptides displaying a biological or immunological activity of human immune interferon and their use in antiviral, antitumor or anticancer, and immunomodulation agents and methods.
Inventors
- 👤 Walter Charles Dr. Fiers
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 17:13
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/70; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
53 words
A DNA sequence selected from the group consisting of the DNA insert of pHIIF-SV-y o , DNA sequences which hybridize to the foregoing DNA insert and which code for polypeptides of the IFN-y type, and DNA sequences which code for a polypeptide coded for by any of the foregoing DNA sequences and inserts.
Claim 2
Dependent Claim
53 words
A DNA sequence selected from the group consisting of the DNA insert of pHIIF-SV-y o , DNA sequences which hybridize to the foregoing DNA insert and which code for polypeptides of the IFN-y type, and DNA sequences which code for a polypeptide coded for by any of the foregoing DNA sequences and inserts.
Claim 3
Dependent Claim
92 words
A DNA sequence according to claim 1 wherein the DNA sequence which hybridizes to said DNA insert is selected from the group consisting of the DNA inserts of pHIIF-SV-γ 1 , pHIIF-SV- Y2 , pHIIF-SV-y 3 , PHIIF-SV-y s , pHIIF-SV-γ 6 , pHIIF-SV-γ 8 , pHIIF-SV-yg, pHIIF-SV-γ 10 , pHIIF-SV-y ll , DNA sequences which hybridize to any of the foregoing DNA inserts and which code for polypeptides of the IFN-y type, and DNA sequences which code for a polypeptide coded for by any of the foregoing DNA sequences and inserts.
Claim 4
Dependent Claim
71 words
A DNA sequence according to claim 1 or 2 wherein the DNA sequence which hybridizes to said DNA insert is selected from the group consisting of the IFN-y related sequences of λCH4A-gHIIF=1 and XCH4A-gHIIF-2, DNA sequences which hybridize to any of the foregoing DNA sequences and which code for polypeptides of the IFN-y type, and DNA sequences which code for a polypeptide coded for by any of the foregoing DNA sequences.
Claim 5
Dependent Claim
23 words
A DNA sequence according to any one of claims 1 to 3 selected from the group consisting of DNA sequence of the formula:
Claim 6
Dependent Claim
29 words
A recombinant DNA molecule comprising a DNA sequence, said DNA sequence being selected from the group consisting of DNA sequences according to any one of claims 1 to 4.
Claim 7
Dependent Claim
21 words
.6. The recombinant DNA molecule according to claim 5, wherein said DNA sequence is operatively linked to an expression control sequence.
Claim 8
Dependent Claim
63 words
The recombinant DNA molecule according to claim 6, wherein said expression control sequence is selected from the group consisting of a lac system, a β-lac system, a trp system, major operator and promotor regions of phage λ, the control region of fd coat protein, other sequences which control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof.
Claim 9
Dependent Claim
40 words
The recombinant DNA molecule according to claim 6 or 7 selected from the group consisting of pHIIF-SV-y o and recombinant DNA molecules related to pHIIF-SV-y s and pHIIF-SV-y lo but having the IFN-y related DNA insert in the opposite orientation.
Claim 10
Dependent Claim
17 words
The recombinant DNA molecule of claim 6 or 7 selected from the group consisting of and pSV2-IFN-y.
Claim 11
Dependent Claim
19 words
A host transformed with at least one recombinant DNA molecule according to any one of claims 5 to 9.
Claim 12
Dependent Claim
36 words
The host of claim 10 selected from the group consisting of strains of E. coli, Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus, other bacilli, yeasts, other fungi, mouse or other animal or plant hosts and human tissue cells.
Claim 13
Dependent Claim
58 words
The transformed host according to claim 10 or 11 selected from the group consisting of strains of E.coli, Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus, other bacilli, yeasts, other fungi, mouse or other animal or plant hosts or human tissue cells transformed with insert DNA selected from the group consisting of γ 1 , γ 5 and γ 10 .
Claim 14
Dependent Claim
27 words
The transformed host according to claim 10 or 11 selected from the group consisting of eukaryotic hosts tranformed with the IFN-y related inserts of λCH4A-gHIIF-1 or XCH4A-gHIIF-2.
Claim 15
Dependent Claim
56 words
The transformed host according to claim 10 or 11 selected from the group consisting of E. coli Kl2ΔHIΔtrp (HIIF-52), E. coli SG4044 (pcI857) ( ), CHO (DHFR - ) (E-10B), CHO (DHFR - ) (E-10C), CHO (DHFR - ) (E-10B3), CHO (DHFR - ) (E-10C6), CHO (DHFR ) (E-10C101) and CHO (DHFR ) (R-10C101 250 nM).
Claim 16
Dependent Claim
26 words
A polypeptide displaying an immunological or biological activity of human immune interferon produced by the transformed host according to any one of claims 10 to 13.
Claim 17
Dependent Claim
18 words
A polypeptide displaying an immunological or biological activity of IFN-y produced by the transformed host of claim 15.
Claim 18
Dependent Claim
47 words
A glycosylated IFN-y produced by a transformed host selected from the group consisting of CHO (DHFR - ) (E-10B), CHO (DHFR - ) (E-10C), CHO (DHFR - ) (E-10B3), CHO (DHFR - ) (E-10C6), CHO (DHFR - ) (E-10C101), and CHO (DHFR - ) (R-10C101 250 nM).
Claim 19
Dependent Claim
47 words
A glycosylated IFN-y produced by a transformed host selected from the group consisting of CHO (DHFR - ) (E-10B), CHO (DHFR - ) (E-10C), CHO (DHFR - ) (E-10B3), CHO (DHFR - ) (E-10C6), CHO (DHFR - ) (E-10C101), and CHO (DHFR - ) (R-10C101 250 nM).
Claim 20
Dependent Claim
25 words
. A polypeptide or fragments or derivatives thereof that is coded for by a DNA sequence according to any one of claims 1 to 4.
Claim 21
Dependent Claim
25 words
A polypeptide or fragments and derivatives thereof according to anyone of claims 13 to 17 selected from the group consisting of polypeptides of the formula:
Claim 22
Independent Claim
29 words
A method for producing a recombinant DNA molecule comprising the step of introducing into a cloning vehicle a DNA sequence according to any one of claims 1 to 4.
Claim 23
Dependent Claim
47 words
The method according to claim 20 comprising the additional step of introducing into said cloning vehicle an expression control sequence according to claim 7, said expression control sequence being introduced into said cloning vehicle so as to control and to regulate the expression of said DNA sequence.
Claim 24
Independent Claim
45 words
A method for producing a polypeptide displaying an immunological or biological activity of human immune interferon, comprising the steps of transforming an appropriate host with a recombinant DNA molecule according to any one of claims 6 to 9; culturing said host; and collecting said polypeptide.
Claim 25
Dependent Claim
37 words
The method according to claim 22, wherein the host is selected from the group consisting of strains of E. coli, Pseudomonas, Bacillus subtilis, Bacillus ,stearothermophilus, other bacilli, yeasts, fungi, animal or plant hosts, and human tissue cells.
Claim 26
Independent Claim
42 words
A method for producing a polypeptide displaying an immunological or biological activity of human immune interferon comprising the steps of culturing a host transformed by a recombinant DNA molecule according to any one of claims 6 to 9 and collecting said polypeptide.
Claim 27
Dependent Claim
49 words
A process for selecting a DNA sequence coding for a polypeptide displaying an immunological or biological activity of HuIFNy from a group of DNA sequences comprising the step of determining which of said DNA sequences hybridize to a DNA sequence according to any one of claims 1 to 4.
Claim 28
Dependent Claim
46 words
A process for selecting a DNA sequence coding for a polypeptide displaying an immunological or biological activity of a non-human immune interferon comprising the step of determining which of said DNA sequences bydridize to a DNA sequence according to any one of claims 1 to 4.
Claim 29
Dependent Claim
47 words
The process of claim 25 or 26 wherein said DNA sequence screened is selected from the group consisting of DNA sequences from natural sources, synthetic DNA sequences, DNA sequences from recombinant DNA molecules and DNA sequences which are a combination of any of the foregoing DNA sequences.
Claim 30
Dependent Claim
36 words
A composition for treating human viral infections or treating human cancers or tumors which comprises at least one polypeptide selected from the group consisting of a polypeptide according to any one of claims 15 to 19.
Claim 31
Dependent Claim
34 words
A method for treating human viral infections or treating human cancers or tumors which comprises administering to said humans in a pharmaceutically acceptable manner an effective amount of a composition according to claim 28.
Claim 32
Dependent Claim
31 words
A composition for use as an immunomodulation agent which comprises at least one polypeptide selected from the group consisting of a polypeptide according to any one of claims 15 to 19.
Claim 33
Dependent Claim
23 words
A method for immunomodulation which comprises administering in a pharmaceutically acceptable manner an effective amount of a composition according to claim 30. .
Claim 34
Dependent Claim
12 words
The use of pharmaceutically acceptable antibodies to IFN-y to counteract allograft rejection.
Claim 35
Dependent Claim
12 words
The use of pharmaceutically acceptable antibodies to IFN-y to counteract allograft rejection.
Claim 36
Dependent Claim
19 words
The use of pharmaceutically acceptable IFN-y to activate macrophages against tumors and cancers and against bacterial and parasitic infections.
Claim 37
Dependent Claim
19 words
The use of pharmaceutically acceptable IFN-y to activate macrophages against tumors and cancers and against bacterial and parasitic infections.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.